Recent News

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer

Natick, MA, October 29, 2020—AffyImmune Therapeutics today announced enrollment of the first patient in its Phase I clinical study evaluating AIC100, the company’s novel affinity-tuned CAR-T cell product, in patients with advanced, refractory thyroid cancer. The trial is designed to test safety, biological activity and real-time assessment of CAR T cell [...]

AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research

June 29, 2020 – AffyImmune Therapeutics, Inc. disclosed novel advancements in their proprietary affinity-tuned CAR T-cell programs and technology in three presentations at the recent Annual Meeting of the American Association for Cancer Research (AACR). One presentation reported on a new CAR T design for localized and inducible cytokine release. The [...]

AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR T cells for Patients with Advanced, Refractory Thyroid Cancer

Natick, MA, October 30, 2019—AffyImmune Therapeutics, an emerging leader in CAR-T therapies, today announced FDA approval of the company’s investigational new drug (IND) application for AIC100, an affinity-tuned CAR T cell that received Orphan designation for advanced thyroid cancer. The trial: Phase I study of AIC100 in relapsed and or refractory [...]